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Abstract
Background: Cyclooxygenase-2 (COX-2) is a key enzyme involved in the conversion of arachidonic acid into prostaglandins.
COX-2 is mainly induced at sites of inflammation in response to proinflammatory cytokines such as interleukin-1a/b,
interferon-c and tumor necrosis factor-a produced by inflammatory cells.
Aim: The aim of this study was to investigate the possible modulating effect of the functional COX-2 polymorphisms 21195
ARG and 2765GRC on the risk for development of inflammatory bowel disease (IBD) in a Dutch population.
Methods: Genomic DNA of 525 patients with Crohn’s disease (CD), 211 patients with ulcerative colitis (UC) and 973 healthy
controls was genotyped for the 21195 ARG (rs689466) and 2765GRC (rs20417) polymorphisms. Distribution of genotypes
in patients and controls were compared and genotype-phenotype interactions were investigated.
Results: The genotype distribution of the 21195ARG polymorphism was not different between the patients with CD or UC
and the control group. The 2765GG genotype was more prevalent in CD patients compared to controls with an OR of 1.33
(95%CI 1.04–1.69, p,0.05). The 2765GC and 2765CC genotype carriers showed a tendency to be less frequent in patients
with CD compared to controls, with ORs of 0.78 (95%CI: 0.61–1.00) and 0.49 (95%CI 0.22–1.08), respectively. Combining
homozygous and heterozygous patients with the 2765C allele showed a reduced risk for developing CD, with an OR of 0.75
(95%CI: 0.59–0.96). In the context of this, the G21195G2765/A21195C2765 diplotype was significantly less common in patients
with CD compared to controls, with an OR of 0.62 (95%CI: 0.39–0.98). For UC however, such an effect was not observed. No
correlation was found between COX-2 diplotypes and clinical characteristics of IBD.
Conclusions: The 2765GRC polymorphism was associated with a reduced risk for developing Crohn’s disease in a Dutch
population.
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Introduction
Inflammatory bowel disease (IBD) is an idiopathic, chronic,
relapsing auto inflammatory disorder of the gastro-intestinal tract.
The two major types of IBD are Crohn’s disease (CD) and
ulcerative colitis (UC). Genetic, immunological and environmental
factors are thought to play a role in the pathogenesis of IBD [1]. A
dysregulated immune response against the intestinal microbiota in
genetic susceptible individuals has been heavily implicated in the
pathogenesis of inflammatory bowel disease [2]. Therefore, genes
involved in inflammatory responses are under investigation to look
for variants predisposing to IBD.
Cyclooxygenase (COX) is a modifier gene and key enzyme in
the conversion of free arachidonic acid into prostaglandins and is
involved in the regulation of inflammatory processes through its
products, mainly prostaglandin E2 (PGE2) [3]. The COX family
consists of two main isozymes: COX-1 and COX-2. COX-1 is
constitutively expressed in most cell types, including the mucosal
compartment of the gastrointestinal tract, and is important for
maintaining mucosal integrity, mucosal defence and regulation of
the mucosal blood flow [4,5]. Being very low expressed in the
normal gut mucosa, COX-2 expression can be induced by
mitogenic and proinflammatory stimuli [5,6].
The relevance of COX-2 in the pathogenesis of IBD has been
demonstrated; increased expression of COX-2 has been observed
in colonic epithelial cells, the myenteric plexus and in the medial
layer of arteries from patients with active IBD [7–9]. In addition, a
relationship between endoscopic activity of IBD and mucosal
COX-2 mRNA levels was noticed [10]. Although COX-2 is
involved in the regulation of inflammatory processes, it also seems
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well as in the maintenance of gastric mucosal integrity when other
defence mechanisms are impaired or COX-1 activity is latent
[3,5]. Moreover, COX-2 seems to be a major contributor to the
processes that lead to resolution of inflammation [11]. In line with
this, the use of non-steroidal anti-inflammatory drugs (NSAIDs) in
patients with IBD, may be associated with exacerbation of the
underlying IBD and gastrointestinal-related complications [12–
14]. Overall, these findings suggest that COX-2 has a dual role by
both initiation as well as resolution of inflammation.
Functional polymorphisms in the COX-2 promoter, being
2765GRC (rs20417) and 21195ARG (rs689466), may alter the
enzyme function of COX-2 by differential regulation of COX-2
expression [15]. Recently, a study by Østergaard et al. reported an
association of the 2765GRC polymorphism with IBD in a Danish
population [16]. Another study from a previous relatively small
sample size study performed in the Netherlands however, showed
no association between these two polymorphisms and IBD [17].
We therefore investigated the COX-2 21195 ARG and
2765GRC polymorphisms in relation to the development and
clinical severity of IBD in a phenotypically well characterized and
relatively large IBD cohort of Dutch origin and hypothesized that
carriers of the 21195 ARG and/or 2765GRC polymorphisms
might be at risk for developing IBD.
Materials and Methods
Patients and controls
This case-control study included 736 patients with inflamma-
tory bowel disease (39% men, mean age 45.0613.9 years), being
525 patients with Crohn’s disease (35% men, mean age
44.5613.9) and 211 patients with ulcerative colitis (48% men,
mean age 46.1614.0) and 973 disease-free controls (43% men,
mean age 47.2616.6 years). All patients were of Dutch origin and
were recruited from the outpatient clinic of the Radboud
University Nijmegen Medical Center, the Netherlands. Controls
were recruited from the Nijmegen area by advertisement in local
papers. The clinical characteristics of the patients are summarized
in Tables 1 and 2. Diagnosis of inflammatory bowel disease was
based on accepted clinical, endoscopic, radiological and histolog-
ical findings [18]. Clinical data of the patients were retrieved by
retrospective collection from patients’ clinical charts. Phenotypes
of the patients were described according to age of onset, necessity
of surgery, family history of IBD, the occurrence of extra-intestinal
manifestations and maximum extent of disease according to the
Vienna [19] and Montreal [20] classifications for Crohn’s disease
and ulcerative colitis respectively.
Information on development of dysplasia and colorectal cancer
(CRC) in our patient cohort was retrieved using PALGA, the
nationwide network and registry of histopathology and cytopa-
thology in the Netherlands [21].
The ethical committee ofregionNijmegen andArnhem reviewed
and approved the protocol under number CWOM-nr 9804-0100.
Verbal informed consent was obtained from each patient before
study participation in agreement with the approval and all samples
were anonymized. Since research data were collected anonymously,
at least verbal informed consent was needed according to national
regulations. Therefore, no written informed consent procedure was
introduced at time of data collection.
Genotyping
Whole blood from patients and healthy controls was obtained
by venapuncture in sterile vacutainer tubes, anti-coagulated with
EDTA and stored at 220uC until use. DNA from patients and
controls was isolated from whole blood using the Pure Gene DNA
isolation kit, according to the instructions of the manufacturer
(Gentra Systems, Minneapolis, MN) and stored at 4uC. Genotypes
of the COX-2 21195ARG polymorphism was determined by
polymerase chain reaction (PCR)-based restriction fragment
length polymorphism assays, as described by Zhang et al [15].
The COX-2 2765GRC polymorphism was determined by a dual-
color discrimination assay using the iCycler iQ Multicolour Real-
Time Detection System (Bio-Rad Laboratories, Hercules, CA), as
described by Peters et al [22].
Statistical analysis
Baseline and clinical characteristics were analysed with standard
descriptive statistics. The observed genotype frequencies were tested
for deviation from the Hardy-Weinberg equilibrium. Estimates of
linkage disequilibrium (LD) between SNPs were determined by
calculating pair-wise D9 and r
2 statistics in unrelated individuals,
using Haploview. Differences in 21195ARG and 2765GRC
genotype distributions between the patient and control groups were
determined by Chi-square analysis. Odds ratios (ORs) with 95%
Table 1. Clinical characteristics of patients with Crohn’s
disease (n=525).
Characteristics (%)
Age at diagnosis 27.1610.7
Family history of IBD* 75/272 (27.6)
Disease localization
Ileal 187 (35.6)
Colonic 127 (24.2)
Ileocolonic 211 (40.2)
Isolated upper disease
+ 36 (6.9)
Disease behaviour CD
Non stricturing, non penetrating 176 (33.5)
Stricturing 89 (17.0)
Penetrating 260 (49.5)
Extra-intestinal disease* 161/491 (32.8)
Peri-anal disease* 180/509 (35.4)
Surgery 320 (61.0)
+Patients could be classified as having disease localisation in the upper
gastrointestinal tract next to ileal, colonic or ileocolonic localisation.
*Note that data of patients are missing.
doi:10.1371/journal.pone.0015011.t001
Table 2. Clinical characteristics of patients with Ulcerative
Colitis (n=211).
Characteristics (%)
Age at diagnosis 32.9612.7
Disease localization*
Proctitis 13/203 (6.4)
Left sided 70/203 (34.5)
Extended/pancolitis 120/203 (59.1)
Surgery 59 (28.0)
*Note that data of 8 patients are missing.
doi:10.1371/journal.pone.0015011.t002
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associated with predicted normal versus predicted altered enzyme
activities (variant genotypes) between IBD patients and controls.
These analyseswerealso applied fortestingofeitherUCorCDwith
the control group. Based on the two polymorphisms investigated, a
diplotype analysis was performed. Diplotypes were compared with
regard to phenotypical characteristics and comparisons were given
as ORs with 95% CI. Additionally, we investigated in patients with
IBDwhetherthe21195ARGand 2765GRCpolymorphismswere
associated with development of mucosal dysplasia or colon cancer.
Data analysis was performed using SPSS software (Version 16.0,
SPSS, Chicago, IL, USA). A p-value of ,0.05 was used as a
criterion for statistical significance.
Results
In this study 736 patients with inflammatory bowel disease, 525
patients with Crohn’s disease and 211 patients with ulcerative
colitis as well as 973 healthy controls were included. No statistical
significant differences were observed between patients with IBD
and controls regarding age and gender. However when the CD or
UC patient groups were compared to controls separately,
significant more females were present in the group with Crohn’s
disease (p,0.01).
Distribution of the 21195 and 2765 COX-2 genotypes in both
patient and control groups fitted the Hardy Weinberg equilibrium;
for the 21195 genotypes, p-values of p=0.14, p=0.17 and
p=0.99, for the patients with Crohn’s disease, ulcerative colitis
and controls were found; whereas corresponding p-values for the
2765 genotypes were p=0.64, p=0.26 and p=0.87, respectively.
As been reported before by others [15,17,23], both SNPs were
found to be in strong linkage disequilibrium (D9=1,r
2=0.05).
Genotype distribution and association with inflammatory
bowel disease
The distribution of the 21195 and 2765 COX-2 genotypes as
found in patients with IBD and controls is given in Table 3. The
21195 genotype distribution was not different between the
patients with Crohn’s disease, ulcerative colitis, or all IBD patients
taken together in comparison with the control group. However,
the 2765 genotype distribution showed a tendency towards a
significant difference between patients with Crohn’s disease and
controls, with the 2765GC and 2765CC genotypes being less
prevalent in patients, with ORs of 0.78 (95%CI 0.61–1.00,
p,0.05) and 0.49 (95%CI 0.22–1.08) respectively and the
2765GG genotype being more prevalent in patients (OR 1.33,
95%CI 1.04–1.69, p,0.05). No differences were found between
patients with ulcerative colitis and controls. Combining homozy-
gous (2765CC) and heterozygous (2765GC) patients bearing the
2765C allele, showed a reduced risk for developing Crohn’s
disease in this group (OR=0.75, 95%CI 0.59–0.96, p,0.05).
The effects of the two COX-2 polymorphisms were then studied
in the context of diplotypes. Six diplotypes were identified, with
the A21195G2765/A21195G2765 diplotype being the most preva-
lent in both patients and controls (Table 4). The G21195G2765/
A21195C2765 diplotype was significantly less frequent in patients
with Crohn’s disease compared to controls with an OR of 0.62
(95%CI: 0.39–0.98, p,0.05).
Correlation of the COX-2 diplotypes with clinical
characteristics of IBD patients
Additionally, clinical characteristics of patients with Crohn’s
disease and ulcerative colitis were studied in the context of
diplotypes in which the most common A21195G2765/A21195G2765
diplotype served as reference. No significant association between
the COX-2 diplotypes and clinical characteristics of either Crohn’s
disease or ulcerative colitis was found (Tables 5 and 6). When data
were corrected for age and gender, no significant changes in data
were observed.
COX-2 polymorphisms and the risk for developing
dysplasia and colon cancer in patients with inflammatory
bowel disease
The PALGA search regarding dysplasia and colon cancer in our
IBD cohort demonstrated that 29 patients (15 patients with CD
and 14 patients with UC) developed mucosal dysplasia, which is
regarded as a pre-malignant phase of CRC. Furthermore, in the
CD cohort 7 patients with CRC were identified; 4 having the
A21195G2765/A21195G2765 diplotype and 3 having the
G21195G2765/A21195G2765 diplotype. In the UC cohort, no
patients were identified who developed CRC. When tested, no
association was found between the COX-2 diplotypes and the
development of colonic dysplasia or cancer (Tables 5 and 6).
Discussion
This study was performed to determine the possible modulating
effect of the COX-2 21195 ARG and 2765GRC polymorphisms
Table 3. Distribution of the COX-2 21195 and 2765 genotypes and corresponding ORs in patients with IBD, CD or UC versus
controls.
Genotype
COX-2
All patients with IBD
(n=736)
Patients with Crohn’s
disease (n=525)
Patients with Ulcerative
Colitis (n=211)
+ Controls
Number
(%) OR (95% CI) p-value
Number
(%) OR (95% CI) p-value
Number
(%) OR (95% CI) p-value n=973 (%)
21195AA 476 (64.7) Reference - 339 (64.6) Reference - 137 (64.9) Reference - 618 (63.5)
21195GA 221 (30.0) 0.91 (0.74–1.12) 0.38 159 (30.3) 0.92 (0.73–1.16) 0.48 62 (29.4) 0.89 (0.64–1.23) 0.48 315 (32.4)
21195GG 39 (5.3) 1.27 (0.80–2.00) 0.31 27 (5.1) 1.23 (0.74–2.04) 0.42 12 (5.7) 1.35 (0.69–2.65) 0.38 40 (4.1)
2765GG 535 (73.2) Reference - 394 (75.0) Reference - 141 (68.4) Reference - 675 (69.4)
2765GC 179 (24.5) 0.84 (0.67–1.04) 0.11 123 (23.4) 0.78 (0.61–1.00) 0.05 56 (27.2) 0.99 (0.71–1.40) 0.97 270 (27.7)
2765CC 17 (2.3) 0.77 (0.42–1.41) 0.39 8 (1.5) 0.49 (0.22–1.08) 0.07 9 (4.4) 1.53 (0.71–3.33) 0.27 28 (2.9)
+In the ulcerative colitis group, there are some missing data (n=5) due to unsuccessful PCR for the 2765 GRC polymorphism.
OR=Odds ratio; CI=confidence interval.
doi:10.1371/journal.pone.0015011.t003
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the 2765C allele showed a reduced risk for developing CD. This
result suggests that the 2765GRC change induces an altered
enzyme expression and enzyme activity with potential anti-
inflammatory consequences.
Studies regarding the functional consequences of the
2765GRC polymorphism in the COX-2 promoter are conflicting.
Therefore, the (physiological) consequences of our findings are
difficult to interpret. First of all, the 2765C-containing COX-2
promoter was reported to drive lower reporter gene expression in
vitro compared to the 2765G-containing counterpart [15,24].
Furthermore, serum prostaglandin E2 (PGE2) concentrations of
renal transplant recipients patients with the GG genotype were
significantly higher than PGE2 concentrations from patients with
the C allele [25]. Subsequent work from Zhang and coworkers
showed that the 2765GRC polymorphism creates a binding site
for nucleophosmin (NPM) and phosphorylated nucleophosmin (p-
NPM), which acts as an inhibitor of COX-2 transcription [26].
The 21195 ARG polymorphism creates a c-MYB binding site,
which can activate COX-2 expression, and displays a higher
promoter activity [15].
In normal colorectal mucosa COX-2 expression is enhanced in
patients with IBD when compared to subjects with normal
colonoscopy [27]. Taken together in light of our results, this would
imply that low levels of COX-2 are associated with an reduced risk
for developing CD. In vitro however, when cells were treated with
smoking condensate, the 2765C-containing promoter exerted a
significantly higher reporter gene expression compared to the
2765G-containing counterpart [26]. Besides this, Szczeklik and
co-workers reported an increased production of prostaglandin E2
and D2 (PGE2 and PGD2) by monocytes obtained from female
patients with asthma who were homozygous for the 2765C
variant of the COX-2 gene [28,29]. In the context of IBD, PGE2
appears to play a dual role. In IBD, PGE2 production is increased
[30] and in an experimental model of IBD high levels of PGE2
exacerbate inflammation [31]. On the other hand, PGE2 signaling
is required for suppressing colitis symptoms and protecting
mucosal damage by maintaining the integrity of the epithelial
intestinal wall, presumably through the enhancement of epithelial
survival and regeneration [32]. Furthermore, PGE2 has been
recently identified to promote naive T cell differentiation to IL-17
– producing T helper (Th17) cells, a subset of T helper cells which
have been implicated as potent effector cells in IBD [33].
Several limitations of our study should be noticed. First of all we
were not able to retrieve the smoking status of our patients and
controls, as Zhao et al. [26] demonstrated an effect of smoking on
the expression of the 2765GRC polymorphism. Secondly, the
effect of the COX-2 21195 ARG and 2765GRC polymorphisms
on colonic mucosal COX-2 expression and/or PGE2 production
in patients with IBD is unknown. However regardless of these
data, the functional consequences of PGE2 in IBD still remains
conflicting as pointed out above.
The results of our study are in conflict with a Danish case
control study by Østergaard et al. who identified that carriers of
the homozygous 2765CC variant had a relatively high risk for
developing CD as well as UC, with an OR of 2.78 (95%CI=1.33–
5.88, p=0.006) and 2.63 (95%CI=1.35–5.26, p=0.005) respec-
tively [16]. The 2765CC variant however is very rare in our
population of IBD patients (n=17, 2.3%) and controls (n=28,
2.9%) as is the case in another Dutch study by Cox et al. in which
(2.4%) of the patients and (2.4%) of the controls had this variant
[17]. In the study of Cox et al., no significant association between
the 21195 ARG and 2765GRC polymorphisms and IBD was
found, although the number of patients with IBD involved
(n=291) was rather small. However, a recent subsequent study
from the Danish group of Østergaard and co-workers extended
the original data with data from Scottish IBD patients and showed
no association any more with the 2765GRC polymorphism and
development of IBD [34]. The differences between our results and
the Danish and Scottish findings could be attributed to the fact
that the genetical contribution to the etiology of IBD in the
northern part of Europe differs from central Europe. Mutations in
the three common CD-associated variants of CARD15, R702W,
G908R and 1007fsinsC, are relatively rare in Northern countries
including Denmark and Scotland, while the mutation frequencies
are relatively high in Central Europe [35].
As stated before, patients with IBD show increased expression of
COX-2 in the gastrointestinal tract [7,8,10,27]. This increased
expression of COX-2 has also been observed in gastrointestinal
adenocarcinomas and in UC-associated neoplasia [36,37]. Addi-
Table 4. COX-2 diplotype distribution and corresponding ORs in patients with IBD, CD or UC versus controls.
Patients with IBD
Diplotype
COX-2 All patients Crohn’s disease Ulcerative colitis Controls
n=731
(%) OR (95% CI) p-value
n=525
(%) OR (95%CI) p-value
n=206
(%) OR (95%CI) p-value n=973 (%)
A21195G2765/
A21195G2765
322 (43.8) Reference - 237 (45.1) Reference - 85 (40.3) Reference - 395 (40.6)
G21195G2765/
A21195G2765
174 (23.6) 0.90 (0.70–1.15) 0.38 130 (24.8) 0.91 (0.70–1.19) 0.49 44 (20.9) 0.86 (0.58–1.28) 0.45 238 (24.5)
A21195G2765/
A21195C2765
133 (18.1) 0.84 (0.65–1.10) 0.20 94 (17.9) 0.81 (0.60–1.08) 0.15 39 (18.5) 0.93 (0.62–1.42) 0.75 194 (19.9)
G21195G2765/
A21195C2765
46 (6.5) 0.72 (0.49–1.07) 0.11 29 (5.5) 0.62 (0.39–0.98) 0.04 17 (8.1) 1.01 (0.57–1.80) 0.97 78 (8.0)
G21195G2765/
G21195G2765
39 (5.3) 1.20 (0.75–1.90) 0.45 27 (5.1) 1.13 (0.67–1.88) 0.65 12 (5.7) 1.39 (0.70–2.77) 0.34 40 (4.1)
A21195C2765/
A21195C2765
17 (2.3) 0.75 (0.40–1.39) 0.35 8 (1.5) 0.48 (0.21–1.06) 0.06 9 (4.3) 1.49 (0.68–3.28) 0.32 28 (2.9)
OR=Odds ratio; CI=confidence interval.
doi:10.1371/journal.pone.0015011.t004
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PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e15011tionally, the COX-2 21195 ARG and 2765GRC polymorphisms
were demonstrated to influence the expression of COX-2 and
confer a risk for developing (adeno)carcinomas in the gastrointes-
tinal tract [15,38,39]. Chronic intestinal inflammation-associated
colorectal carcinogenesis is thought to occur via a stepwise
progression beginning with epithelial hyperplasia, leading to
various grades of dysplasia, adenoma, and then to adenocarcino-
ma [40]. We investigated whether or not an association could be
found between the COX-2 polymorphisms and dysplasia or CRC
in patients with IBD. Due to the restricted number of patients who
developed dysplasia or CRC, no differences could be observed.
In conclusion, subjects with the 2765C allele showed a reduced
risk for developing CD. No correlation could be found between
the COX-2 diplotypes and clinical characteristics of IBD patients
and the development of colonic dysplasia or cancer. Further
studies are required to confirm the association we found and
efforts should be made to unravel the role of COX-2 and its
derived prostaglandins in the pathogenesis of IBD.
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